earnings
confidence high
sentiment neutral
materiality 0.75
uniQure reports Q2 loss of $37.7M; FDA agrees on AMT-130 BLA pathway for Q1 2026 submission
uniQure N.V.
2025-Q2 EPS reported
-$1.49
revenue$6,829,000
- Revenue $5.3M, down from $11.1M YoY; net loss $37.7M ($0.69/share).
- FDA alignment on SAP and CMC for AMT-130 BLA; topline three-year data in Sept 2025.
- AMT-260 first patient showed 92% seizure reduction at 5 months with no serious AEs.
- Cash $377M expected to fund operations into H2 2027.
- Appointed Kylie O’Keefe as Chief Customer and Strategy Officer.
item 2.02item 9.01